It has materialized in lights of restless efforts of domestic pharmacologists and the support provided by Science and Technology Department of the Presidential Office, Mehr News Agency said.
Made of baby hamster kidney fibroblasts, AryoSeven is a recombinant form of human factor VII.
It is prescribed for hemophilia patients (with Factor VIII or IX deficiency) who have developed inhibitors against replacement coagulation factor.
Dr. Fereydoun Mahboudi, the head of Factor VII project, said Factor VII is one of the proteins that cause blood to clot in the coagulation cascade. It is an enzyme of the serine protease class, he added.
The main role of Factor VII (FVII) is to initiate the process of coagulation in conjunction with tissue factor (TF/factor III). Tissue factor is found on the outside of blood vessels, normally not exposed to the bloodstream.
Upon vessel injury, tissue factor is exposed to the blood and circulating factor VII.
Once bound to TF, FVII is activated to FVIIa by different proteases, among which are thrombin (factor IIa), factor Xa, IXa, XIIa, and the FVIIa-TF complex itself.
The complex of factor VIIa with TF catalyzes the conversion of factor IX and factor X into the active proteases, factor IXa and factor Xa, respectively.
The action of the factor is impeded by tissue factor pathway inhibitor (TFPI), which is released almost immediately after initiation of coagulation. Factor VII is vitamin K dependent. It is produced in the liver. Use of warfarin or similar anticoagulants decreases hepatic synthesis of FVII.
"Many countries seek to produce this vital medicine. Iran is the second country which can make FVII," Mahboudi added.
"We are to export FVII to Russia and Turkey. All the licenses and standards in this regard have been obtained. Currently, we seek to receive license for exporting the product to EU."
The Danish copy of the drug is priced $1000 a package, while the Iranian one is sold one-third of that to Drug and Food Organization.